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Unstructured summary: 143/200 words 25 
Early in the COVID-19 pandemic, models predicted hundreds of thousands of additional tuberculosis (TB) 26 
deaths as a result of health service disruptions. To date, empirical evidence of the effects of COVID-19 on 27 
TB outcomes has been limited. Here we summarize the evidence available at a country level, identifying 28 
broad mechanisms by which COVID-19 may modify TB burden and mitigation efforts. 29 
 30 
Where data are available, it is clear that there have been substantial TB health service disruptions and an 31 
increase in vulnerability to TB. Evidence for changes in Mycobacterium tuberculosis transmission is limited, 32 
and it is unclear how the resources required and available for the TB response have changed. To advocate 33 
for additional funding to mitigate the impact of COVID-19 on the global TB burden, and to efficiently allocate 34 





Given concerns for maintaining TB care and prevention services during the COVID-19 pandemic,1 38 
mathematical modelers have attempted to estimate the potential impact of program disruptions on TB 39 
incidence and mortality.2-5 Despite the use of different methods and assumptions about the future of the 40 
pandemic, as well as modelling a variety of settings including India, China, South Africa, Kenya, Ukraine  41 
and Brazil, these analyses reached broadly similar conclusions. Specifically, TB incidence, and especially 42 
TB mortality, are projected to increase by around 5-15% over the next 5 years, amounting to hundreds of 43 
thousands of additional TB deaths worldwide during that time. These early modeling analyses, however, 44 
relied on a number of assumptions, which should ideally be re-evaluated in the context of empirical data. 45 
Since these analyses were produced, little empirical evidence has been systematically collected to quantify 46 
the impact of COVID-19 on TB burden. A data-driven understanding of this impact is necessary to support 47 
efforts to mitigate it, revising the implementation of TB services and the allocation of resources to different 48 
TB interventions. To implement and prioritise effectively, it is essential to understand the current situation. 49 
 50 
We expect COVID-19 to affect TB outcomes differently by setting. For example, countries with large TB 51 
burden such as India and Viet Nam have experienced very different COVID-19 incidence.6 Countries with 52 
similar COVID-19 burden such as Brazil and Argentina have experienced very different health system 53 
disruptions.7 Indeed, within individual countries the impact will further vary between rural and urban areas, 54 
by socioeconomic status, and as response measures vary spatially. With all of this variation, it is therefore 55 
important to focus on the measurement of setting-specific impact. It is also important to identify when the 56 
impact was measured, as the temporal effect of the pandemic varies between countries. 57 
 58 
Here we review the evidence available, to inform the revision of both implementation and allocation of 59 
resources by TB programmes. We identify where country-specific data and evidence can be found to 60 
quantify the impact of COVID-19 on TB outcomes, and the costs of any mitigation. We outline in Figure 1 61 
the conceptual framework to scope our narrative review, specifying how COVID-19 may impact across the 62 
TB care cascade, identifying disruptions to TB health service delivery and changes in demand, alterations 63 
in vulnerability to TB (including comorbidities and risk factors), and opportunities for Mycobacterium 64 
tuberculosis (Mtb) transmission. Lastly, we identify data on the impact of COVID-19 on both availability and 65 
requirements of  TB resources. We collate this evidence in Table 1, and end by highlighting knowledge 66 
gaps which should be prioritized for study. 67 
 68 
Search strategy and selection criteria 69 
 70 
We conducted a narrative and bibliometric review, combining a rapid semi-systematic search and 71 
convening a range of experts. For the rapid review references were identified through searches of PubMed, 72 
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medRxiv and bioRxiv for articles published from January 2020 to January 2021, using the terms “COVID” 73 
or “SARS” or “corona”, and “TB” or “tuberculosis”. In addition, literature relevant to TB vulnerabilities, Mtb 74 
transmission and TB resources was identified through the authors’ personal libraries. Additional relevant 75 
grey literature was identified through communication with the WHO Global TB Department, as well as 76 
through a virtual meeting of the TB Modelling and Analysis Consortium, where a group of TB experts from 77 
global agencies, academic institutions and country programmes were invited to identify additional sources 78 
of data and to confirm and highlight priority knowledge gaps. Grey literature were included in this instance 79 
as they represent a significant proportion of the relevant data available to country-level TB decision makers 80 
when making policy choices. Articles resulting from these searches and relevant references cited in those 81 
articles were reviewed. 82 
 83 
Articles which contained data on country-specific quantitative changes to TB health service indicators, 84 
burden of TB vulnerabilities, Mtb transmission and TB resources for the World Health Organization high 85 
TB, TB/HIV and multidrug-resistant (MDR) TB burden countries were included, and data extracted from 86 
these articles. A summary of sources found by country on each topic is presented in Table 1. We provide 87 
a narrative synthesis of our findings below. Ethical approval was not required for this study. 88 
 89 
Tuberculosis health services 90 
 91 
The provision of TB health services (TB diagnosis, care and prevention services), and access to these 92 
services, has been severely disrupted by COVID-19.8-10 TB service providers across many high TB burden 93 
contexts have faced difficulties in service provision, due to lack of appropriate equipment and capacity, 94 
restrictions to movement (affecting health care workers, commodities and stock), and reallocation of 95 
resources.9 Meanwhile, individual TB patients have struggled to access TB services, whether through fear 96 
of SARS-CoV-2 infection, fear of stigma, restrictions to movement, reduced health facility opening hours, 97 
or reductions in ability to pay for care or transport.8 Globally, TB diagnosis, care and prevention has been 98 
affected as a result. However, nearly a year after these disruptions first hit, very little high-level information 99 
is available, focused primarily on reductions in the number of TB patients.11 Most data that are available 100 
focus on the first two quarters of 2020, with very little data except for patient numbers available for quarters 101 
three and four when services might be expected to be somewhat restored. 102 
 103 
Most high TB burden countries have observed some changes in TB case numbers or notifications (when 104 
TB is diagnosed in a patient and this is reported through the national surveillance system) that have resulted 105 
due to COVID-19.12-31 Continuous surveillance systems and current data collection efforts32,33 suggest that 106 
additional data may also be forthcoming. In general, TB notifications decreased significantly during the early 107 
stages of the pandemic compared to previous years. The United States Agency for International 108 
Development preliminarily estimates that over 1 million fewer cases in 24 high TB burden countries alone 109 
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may have been notified in 2020 as a result of the pandemic, with a 7% relative reduction in Africa, a 15% 110 
reduction in Central Asia and Europe and a 27% reduction in Asia compared to 2019.34 A limited number 111 
of countries appear to have either avoided this trend (such as Mozambique and Tanzania) or have seen 112 
notifications dip and since recover to pre-pandemic levels (such as China and Viet Nam).12 However, 113 
without data on TB testing and positivity rates it is difficult to determine whether this widespread decrease 114 
in notifications reflects a true decrease in incidence, or a decrease in access to TB diagnostic services. In 115 
several countries where testing data, including for drug sensitivity testing, are available (China,15-17 116 
Nigeria,35 the Philippines36 and South Africa37, with further studies underway in Kenya, Malawi and 117 
Zimbabwe38, as well as Brazil, Uganda and Viet Nam39), testing decreased. In South Africa this was 118 
accompanied by a corresponding increase in TB test positivity (the proportion of TB tests which were 119 
positive).37 The implication of this is that there are likely to be large numbers of undiagnosed cases of TB 120 
in the community, who may now face poorer treatment outcomes due to delayed diagnosis and treatment.  121 
 122 
In addition to reducing TB diagnosis, COVID-19 related disruptions may hamper treatment for TB patients 123 
due to limited treatment support and medication stockouts. Such disruptions could increase the risk of 124 
treatment interruption and delay, and decrease treatment adherence, which can be expected to result in 125 
worsening TB treatment outcomes. Due to the long duration of TB treatment, definitive data on changes in 126 
TB treatment outcomes as a result of COVID-19 may not be available for several months. In small reports 127 
of patients in private-sector centres in Pakistan,40 a Chinese province16 and cities in Ethiopia41 and 128 
Zimbabwe,24 treatment outcomes and support have worsened slightly (~5-15% relative reduction). On the 129 
other hand, analysis of data from China17 and of a small number of patients in cities in Kenya and Malawi24 130 
did not show strong evidence of a significant reduction in treatment success, and non-TB-specific data in a 131 
South African province showed that numbers of clinic visits in general did not decline, although there was 132 
a significant (but temporary) decrease in child healthcare visits.42 Further studies are underway in Brazil, 133 
Uganda and Viet Nam.39 At this point, it is difficult to determine how effective calls for the use of digital 134 
technologies, additional medicines to take home and other approaches to ensure adequate treatment43 135 
have been, although many patients have reported feeling insufficiently supported.8 136 
 137 
TB prevention services such as routine BCG vaccination, household contact management and preventive 138 
therapy are also likely to have been impacted by the COVID-19 pandemic. Routine reporting on these 139 
indicators is limited, and this challenges efforts to quantify the impact of COVID-19 on provision of these 140 
preventive services. TB centres in Brazil,25 Kenya,25 the Philippines36, Russia,25 South Africa,44 Sierra 141 
Leone25 and Zambia45 reported relative declines in preventive therapy enrollment of 30-70%, although in 142 
the Philippines this decline appears to be consistent with pre-pandemic recent trends, and in South Africa 143 
as well as one Brazilian centre, preventive therapy enrollment seems to have recovered to pre-COVID 144 
levels. Meanwhile, India31,46 and Pakistan47,48 reported major decreases in relative BCG vaccination 145 




Vulnerability to tuberculosis 148 
 149 
As the COVID-19 pandemic has impacted TB burden, so it has also impacted global vulnerability to TB, 150 
through a general decrease in health care access, an increase in poverty and the potential for post-COVID-151 
19 lung diseases. These vulnerabilities could increase progression to TB disease amongst those with Mtb 152 
infection, as well as worsen treatment outcomes for patients on treatment. Modelling evidence broadly 153 
suggests that an increase in these vulnerabilities is likely,4,50,51 but clear evidence of an increase is thus far 154 
scarce. 155 
 156 
There is growing evidence to suggest that previous or current TB infection or disease are associated with 157 
poor COVID-19 outcomes, including a roughly two- to threefold increase in mortality (which occurred more 158 
quickly) and a 25% relative decrease in risk of recovery (which occurred more slowly) for COVID-19 159 
coinfection with current TB disease.52-55 However, while there is little evidence as yet that previous SARS-160 
CoV-2 infection or COVID-19 disease affect either progression to TB disease or TB treatment outcomes, 161 
the possibility of post-COVID-19 lung damage and subsequent vulnerability to TB is a major concern.11,56,57 162 
A number of different studies are underway to investigate this issue.58-60 163 
 164 
At the same time, a similar decrease in health care provision to that described above for TB could 165 
significantly impact TB vulnerabilities such as HIV and diabetes. Data for HIV health services are available 166 
from UNAIDS 61 for many, but not all, high TB/HIV burden countries. This includes both testing and 167 
treatment data for Botswana, Ethiopia, Indonesia, Kenya, Lesotho, Mozambique, Myanmar, Peru, Sierra 168 
Leone, Tajikistan, Ukraine and Zimbabwe, testing data only for Brazil, Cambodia, Liberia, Uganda and 169 
Tanzania, (as well as the capital cities of Kenya, Malawi and Zimbabwe24) and treatment data only for 170 
Cameroon, Kyrgyzstan and Nigeria. Broadly, HIV testing has declined significantly due to COVID-19, 171 
particularly in the early stages of the pandemic. However, in many settings this has recovered somewhat, 172 
in particular HIV self-testing.61 In addition, the proportion of tests that are positive has generally not 173 
changed, suggesting that there has likely been relative stability in testing practices if not coverage. 174 
Meanwhile, although numbers on treatment have been less affected, numbers initiating treatment have 175 
declined precipitously and generally not returned to pre-COVID-19 levels.61 However, it is not yet clear how 176 
the actual burden of HIV, diabetes and other TB vulnerabilities has increased due to COVID-19. 177 
 178 
Poverty is expected to increase due to COVID-19,50 and in particular surveys show it is driving people with 179 
TB into poverty and increasing inequities.8 Although data on changes to costs faced by TB patients are not 180 
yet available, national surveys were underway in 2020 or planned for 2021 in 13 of the 48 high TB, TB/HIV 181 
or MDR-TB burden countries.12 In particular, one survey recently completed in India contains samples from 182 
both pre- and mid-pandemic periods. The effects of an increase in poverty and inequality include a likely 183 
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increase in catastrophic costs (>20% of household annual income) faced by TB patients and a resulting 184 
inability to access TB health services as discussed above.62 Increases in poor living conditions and 185 
malnutrition can also drive increases in TB.63,64 With as much as 30-50% of TB incidence attributable to 186 
malnutrition, the potential longer term consequences for these economic effects on the TB epidemic will be 187 
important to investigate.65  188 
 189 
Mycobacterium tuberculosis transmission 190 
 191 
We do not yet know how Mtb transmission has been affected by COVID-19 and the use of interventions to 192 
reduce SARS-CoV-2 transmission. A reduction in respiratory contacts in the community and healthcare 193 
settings, in addition to the widespread use of masks, may reduce transmission of Mtb as has been observed 194 
for influenza.66 However, a potential increase in contact within household settings, and the long duration of 195 
latent TB infection and TB disease as compared to COVID-19, may increase transmission in these settings. 196 
This effect could be compounded if decreasing access to TB health services leads to greater durations of 197 
TB infectiousness and increasing vulnerabilities lead to greater risk of TB disease.  198 
 199 
Studying TB transmission in general is challenging. One approach to estimate potential changes in Mtb 200 
transmission is to consider changes in contacts in different social settings over time, particularly as these 201 
data are collected elsewhere to understand changes to SARS-CoV-2 transmission. Unfortunately, for most 202 
high TB burden countries contact surveys are limited. While synthetic contact matrices are available for all 203 
high TB burden countries except Somalia,67-70 only 10 high TB, TB/HIV or MDR-TB burden countries have 204 
contact surveys available from before the pandemic.71-84 Furthermore, only China85, Kenya86 and South 205 
Africa87 have contact surveys available from during the pandemic (with a survey currently underway in 206 
Pakistan), showing a marked decrease in contacts outside of the household. 207 
 208 
New sources of mobility data, for example from  Google 88 or mobile phone providers, suggest massive, 209 
time-varying changes in population movements as a result of COVID-19. Although this does not provide 210 
information on how contacts have changed, it does allow for a better understanding of locations (such as 211 
public transport or places of worship) where contacts have decreased. This can be used, alongside contact 212 
surveys where the location of contact was recorded, to estimate likely reductions in contacts. A major caveat 213 
is that those surveyed include mobile phone owners only, which may underrepresent both TB patients89 214 
and potentially those unable to practice physical distancing. 215 
 216 
Again as a result of efforts to understand the pandemic, data on mask-wearing are widely available for all 217 
high TB burden countries, and shows a major increase,90,91 which has the potential to be of great benefit to 218 
the TB response.92 Although the impact of mask use on Mtb transmission is poorly understood,93 it may be 219 




The impact on Mtb transmission of changes in contacts or mask-wearing in particular locations is dependent 222 
on the extent to which transmission occurs in those locations and the potential for changes in per-contact 223 
risk to affect overall risk of transmission. Studies from before the pandemic suggest that even for children 224 
as little as 10-30% of population-attributable transmission is due to household exposures.95,96 Presuming 225 
contact saturation within the home limits the amount of additional transmission that could occur as a result 226 
of increased time spent there,97 decreased community contact and mask-wearing could significantly reduce 227 
overall Mtb transmission per person with TB disease. The relative importance of this reduction in community 228 
transmission is likely to be dependent on the extent to which transmission occurs outside of the home. 229 
Some evidence of the proportion of Mtb transmission attributable to the household or other locations is 230 
available for a number of countries, where this may depend in part on the burden of disease.95,98-108 231 
 232 
Tuberculosis resources 233 
 234 
To both understand and mitigate the consequences of COVID-19 on TB interventions and outcomes, it is 235 
necessary to understand how the resource needs of TB services have changed, and the impact of COVID-236 
19 on the resources available to TB. Firstly, approaches to delivering TB interventions are likely to have 237 
changed, either through design (such as an increased need for personal protective equipment or additional 238 
staff time required to undertake infection control and physical distancing measures), or through shortages 239 
or constraints to some inputs (such as staffing and diagnostic capacity).43 Secondly, prices for different 240 
intervention inputs could change substantially as demand increases. Thirdly, the costs of providing services 241 
are linking to service volumes (for example, a short term reduction in demand may result in temporary over 242 
capacity of some TB focused resources). Lastly, the available budget for supporting TB services may be 243 
lower, with resources reprogrammed to COVID-19 care or mitigation. Indeed, nearly half of high TB burden 244 
countries reported reallocation of TB funding to the COVID-19 response,12 with TB funding broadly 245 
decreasing significantly,8. Although additional funding to most countries (apart from Brazil, Cambodia, 246 
China, DPR Korea, Guinea-Bissau, Indonesia, Russian Federation, Sierra Leone, Tajikistan, Thailand and 247 
Tanzania) has been made available by funders such as the Global Fund to Fight AIDS, Tuberculosis and 248 
Malaria,109 this is aimed at mitigating the impact on the HIV, TB and malaria programmes in general, and 249 
does not shed light on any changes to domestic budget available to the TB programme. We found no 250 
country-level quantitative data currently publicly available on the impact of COVID-19 on the resources 251 
available to or required for the TB response. During the expert meeting, researchers confirmed that in the 252 
main cost data collection had been suspended during the COVID-19 period. 253 
 254 
Conclusions 255 
In general, where data are available TB health services appear to have decreased significantly in most 256 
settings due to COVID-19. Numbers of patients, as well as testing and prevention coverage, have 257 
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decreased more noticeably than treatment outcomes, although few data are available on the latter. 258 
Ensuring adequate treatment for known TB patients, through provision of additional medicine and digital 259 
treatment support, certainly appears to be more amenable to physical distancing than TB diagnosis, which 260 
requires more direct contact between individuals. Meanwhile, vulnerability to TB has widely increased. HIV 261 
services appear to have recovered somewhat, although the potential for COVID-19-related lung damage 262 
to lead to widespread vulnerability to TB is still unknown, as are the impacts of changes in other 263 
vulnerabilities such as diabetes and malnutrition. Data on the impact of an increase in poverty on TB patient 264 
costs are currently unavailable, although in many countries studies are underway to address this. Unlike 265 
TB health services, which have in a number of cases been restored to some extent, vulnerabilities are likely 266 
to continue to increase despite COVID-19 vaccines, as widespread poverty remains and SARS-CoV-2 267 
infections continue to climb. While community transmission of Mtb has likely decreased significantly, the 268 
effect of household transmission and a potential increase in cases means that it is difficult to draw any 269 
conclusions on changes to Mtb transmission, and indeed this may never be possible, although the location 270 
of transmission events is certainly highly likely to have shifted. Lastly, while some additional funding has 271 
been allocated by global agencies to countries for their TB response, it remains unclear how overall health 272 
system resource constraints and the changing resources of service delivery are impacting TB. Although it 273 
is difficult to draw any conclusions on the geographic availability of data, we note that little appear to be 274 
available for the high MDR-TB burden countries of Central Asia, while many smaller studies are available 275 
for countries in sub-Saharan Africa. In general, in only a limited number of countries such as China and 276 
South Africa are good data available across a range of indicators. 277 
 278 
When identifying priority gaps that remain for understanding and mitigating the impact of COVID-19 on TB, 279 
it is important to be clear on what these data will be used for; here we suggest that this would primarily be 280 
to allocate TB resources more efficiently and to help advocate for additional resources for the TB response. 281 
The first of these requires a good understanding of the effect on health services, and the resources available 282 
and required to restore these to at least pre-pandemic levels. The second requires in addition an 283 
understanding of how vulnerability to TB and Mtb transmission have changed. In an online meeting of 60 284 
TB experts (TB Modelling and Analysis Consortium meeting on the impact and mitigation of COVID-19 on 285 
TB, held 12 January 2021), a range of priorities were identified from across the four broad areas identified 286 
above; these are outlined in Figure 2. The most strongly supported of these included data on delays to 287 
diagnosis and treatment, changes to patient costs of TB services, the impact of COVID-19 infection and 288 
disease on vulnerability to TB and mortality, and the effect of changing contacts and mobility on household 289 
and community transmission of Mtb. A key priority was the longer-term requirement for more responsive 290 
TB information systems. While this has not been as much of a problem in the past, the rapid nature of the 291 
COVID-19 pandemic has highlighted the need for frequently reported, disaggregated TB health service 292 
availability and use data, to allow for an appropriate response. A lack of real-time data to make decisions 293 
suggests that investment in a change to TB information and reporting systems to enhance real-time 294 
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empirical evidence (as can be seen for COVID-19) is required. Data collation and monitoring efforts, by an 295 
appropriate global stakeholder, should additionally be strengthened. 296 
 297 
In conclusion, while numbers of TB patients have declined globally, it is not yet possible to determine the 298 
key causes for these declines, what they represent in terms of changing TB burden, and what action is 299 
required to mitigate them. In advocating for additional funding to mitigate the impact of COVID-19 on the 300 
global TB burden, and to allocate available resources efficiently for the TB response, a significant 301 
improvement in the availability of TB data is required. 302 
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Table 1: Available or upcoming data on the impact of COVID-19 on TB by country for World Health Organization high TB, TB/HIV and multidrug-resistant TB burden 596 
countries.12 597 
COUNTRY 
HEALTH SERVICES DATA VULNERABILITY DATA TRANSMISSION DATA RESOURCE DATA 
Diagnosis Treatment  Prevention HIV Poverty 
No control 
measures 














































































































































































13           67  88 90   109 
Azerbaijan            67   90   109 
Bangladesh 
13         12 98 67  88 90   109 
Belarus            67  88 90   109 
Botswana        61 61  98 67  88 90   109 
Brazil 
23,25 39  39 39  25 61  12 98,99  67  88 90    
Cambodia 
12       61    67  88 90    
Cameroon         61 12  67  88 90   109 
Central African 
Republic          
 
 67   90 
  109 
Chad            67   90   109 
China 
12,14-17,30  15-17  17 16,17       67,68,71,72 85  91    
Congo            67   90   109 
DPR Korea 
13           67   90    
DR Congo            67   90   109 
Eswatini            67   90   109 
2 
 
Ethiopia 13    41   61 61 12  67   90   109 
Ghana            67  88 90   109 
Guinea-Bissau           98 67  88 90    
India 
12,20,21 
25,27,28 31     31,46    
12 
98 67,68  88 91 
  109 
Indonesia 
12       61 61 12 98 67  88 91    
Kazakhstan            67  88 90   109 
Kenya 12,24,25 38 38  24  25 24,61 61  95,98 67,73,74 86 88 90   109 
Kyrgyzstan         61   67  88 90   109 
Lesotho 
13       61 61   67   90   109 
Liberia        61    67   90   109 
Malawi 
24 38 38  24   24  12 95,100  67,75   90   109 
Mozambique 
12       61 61 12  67  88 90   109 
Myanmar 13       61 61   67  88 90   109 
Namibia 
12         12  67  88 90   109 
Nigeria 
18 35       61  98 67  88 90   109 
Pakistan 22    40 47 48      67  88 90   109 
Papua New 
Guinea          
 
 67  88 90 
  109 
Peru 
13       61 61 12 98,101,102 67,76  88 90   109 
Philippines 
12,25,29 36 36    36     67  88 91   109 
Republic of 
Moldova          
 
 67  88 90 
  109 
Russian 
Federation 
13,25      25   
 
 67,68,77,78   90 
   
Sierra Leone 12,19,25      25 61 61  98 67   90    
3 
 
Somalia               90   109 
South Africa 
12,26 37 37 42   44 61 61 
12 95,98,103-
106 67,68,79-81 87,110 88 90 
  109 
Tajikistan        61 61   67  88 90    
Thailand 12         12  67,69  88 91    
Uganda 
111 39   39   61  
  
95,98,99,107  67,82  88 90 
  109 
Ukraine        61 61   67  88 90   109 
Tanzania 
12       61    67  88 90    
Uzbekistan            67   90   109 
Viet Nam 12 39   39      98,108 67,83  88 91   109 
Zambia 
12 
     




88 90   109 
Zimbabwe 








88 90   109 
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Figure 1: Potential impact of the COVID-19 pandemic on the TB care cascade. Arrows indicate an increase 600 
or a decrease in number of patients at that point of the cascade, including the logic behind the change. 601 
Dark blue arrows indicate an impact of health service delivery and demand, grey arrows indicate an impact 602 
on vulnerability to TB, and light blue arrows indicate an impact on Mtb transmission. 603 
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Figure 2: Outline of priority gaps that remain for understanding and mitigating the impact of COVID-19 on 606 
TB.607 
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